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BRIEF DEFINITIVE REPORT H-IL-3), r-IL-4 (No. H-IL-4) and r-IL-6 (No. H-IL-6, all from Genzyme) were used either alone or in various combinations . The following concentrations were used: IL-1a + /3, 25-50 + 25-50 U/ml; IL-3, 5-15 U/ml; IL-4, 500-1,000 U/ml; IL-6, 200-1,000 U/ml. Antibodies. Polyclonal antibodies (Abs) to p, 6, y, a, K, and X chains directly conjugated with tetraethylrhodamine (TRITC) were from Dakopatts, Glostrup Cell Cultures. PBMC cells (2 x 106/ml) were cultured in 24 Limbro plates (Flow Laboratories, Irvine, CA) for up to 6 d at 37°C and 5% CO2 either alone or in presence of different combinations of cytokines. Cell samples were harvested at days 3 and 6 and analyzed for the morphology, DNA synthesis, and phenotype . The morphology was evaluated with conventional May-Griinwald-Giemsa (MGG) staining on cytocentrifuge slides 
Results
MGG staining (Fig. 1 A) and IF studies with anti-Ig isotypes established that the percentage ofplasma cells in the PBMC seeded at day 0 was between 0.01 and 0.2 %. B cells (CD19+ cells) were 10.2 t 2.8%, T lymphocytes (CD3+ cells) were 63 t 10%, and monocytes (CD14`cells) were 15 ± 5%. The proportion of DNA-synthesizing (Brdu +) cells was 0.13 t 0.06%. Preliminary experiments were performed on these cultured MM PBMC to determine the optimal combinations and concentrations of cytokines using two parameters to assess the cytokine activity: (a) the proportion of Brdu + cells after 3 d of culture and (b) the appearance of plasma cells after 6 d ofculture . These experiments unequivocally showed that the combination of IL-3 (15 U/ml) + IL-6 (1,000 U/ml) concomitantly added to the cultures at day 0 was strikingly active on MM PBMC cells (Table I) . IL-1, IL-3, IL-4, and IL-6 used alone as single stimuli and the varius combinations of IL-1 + IL-3, IL-1 + IL-4, IL-1 + IL-6, IL-3 + IL-4, IL-4 + IL-6 concomitantly added at day 0 were instead ineffective . Likewise inefficient was the priming of MM PBMC with IL-3 (or IL-6) at day 0 followed by the addition of IL-6 (or IL-3) at day 3 . The simultaneous addition to the cultures at day 0 of IL-3 (15 U/ml) + IL-6 (1,000 U/ml) was therefore used throughout the experiments . IL-3; IL-6-induced long-term cultures were not attempted .
MM PBMC Culturedfor 3 din the Presence of IL-3 + IL-6 Give Origin to Proliferating Immunoblast-like B Cells. After 3 d of culture in presence ofIL-3 + IL-6, a population of immunoblast-like cells ( Fig. 1 B) appeared in all the MM samples studied (35 t 12.6%, range 20-62%, Table I ). These large blasts were actively proliferating (8.5 f 2.5% Brdu+ cells, Table I ) and belonged to the B cell lineage as they were HLA- DR', uniformly expressed the B cell-specific CD19 and CD20 antigens (Table II) , while they did not react with the T cell-specific CD3 and the monocyte-specific CD14 mAbs (<I%). Also, these cells were CD38+, but no Ig molecules could be observed on their surface nor in the cytoplasm (Table II) . In 3 of 11 cases, the vast majority (Table I ).
MMPBMC Culturedfor 6 d in Presence ofIL-3 + IL-6 Give Origin to MonoclonalPlasma
Cells. After 6 d ofculture in the presence of IL-3 + IL-6, a population ofmorphologically evident plasma cells (Fig. 1 C) , sometimes binucleated ( Fig . 1 D) , became apparent in all the MM samples studied (38.2 t 6.09%, range 30-50% ; Table I ) . Some large blast-like cells were still present (15 .5 t 4.7%) and these were incorporating Brdu, while the proportion of Brdu + plasma cells was 0.3 t 0.3% (Table  I) . The plasma cells were CD10 -, weakly CD19+, strongly CD38+, PCA-1' (Table  II) . In 3 of 11 cases, the plasma cells expressed in the cytoplasm the same light and heavy chain produced by the BM myeloma cells (Fig. 1 E) : these were the three cases who had produced CD10+ B blasts after 3 d of culture (Table I) . Cytoplasmic monoclonal light and heavy chains were expressed by the plasma cells of all the remaining eight cases, when the initial signal provided by IL-3 + IL-6 was followed by a refeeding of IL-6 (1,000 U/ml) at day 3 . The proportion of morphologically evident plasma cells was 2.5 t 1.2 % in MM control cultures and 0 .6 t 0.3 (Table  I) in normal subjects (Fig . 1 F) .
Discussion In this paper we show that PBMC obtained from MM patients harbor a population of cells that, after exposure to IL-3 and IL-6, develop into proliferating immunoblast-like B cells (Fig . 1 B) and subsequently differentiate into monoclonal plasma cells (Fig . 1, C-E ) . Our findings demonstrate that malignant plasma cell precursors circulate in the PB ofMM patients and establish that their terminal differentiation is promoted by the concerted action of IL-3 and IL-6 . IL-3 supports the proliferation of B cell precursors in the murine lymphohemopoietic system (11, 12) and has been recently shown to be active also on human acute lymphoblastic leukemia B blasts (13) . promotes the differentiation ofactivated B cells (14, 15) , and in con- cert with IL-3, may also effect multipotential stem cells (16) . Further, IL-6 receptors are expressed on the surface of MM plasma cells (17) and indeed IL-6 not only controls the growth of murine malignant plasma cells (18) but also influences the proliferation of human MM cells (17, 19) . It is unlikely that MM precursors have a plasma cell morphology since, in our culture system, high numbers of monoclonal plasma cells were obtained at day 6 even when the plasma cells seeded at day 0 were 0.01% . Likewise, CD10+ cells are not "the" clonogenic cells of MM but appear to represent a hyperactive transition compartment of proliferating pre-plasma cells (20) . This observation provides a biological explanation for the highly aggressive clinical behavior of CD10 + MM, as are defined the cases with a high proportion of BM CD10+ B cells (21) that may eventually spill over in the PB (22) . The IL-3/IL-6 responsiveness of MM circulating plasma cell precursors favors the view that the transforming events of MM occur at an early stage of hematopoiesis (2, 5, 20) . Our findings suggest the likely dynamics ofprecursor-plasma cell transition within the MM malignant clone. MM plasma cell precursors have IL-3 and IL-6 receptors, circulate and find the appropriate microenvironment enriched in IL-3 + IL-6 in the BM, where they first transform into actively proliferating blast-like cells possibly expressing the CD10 antigen, and then they develop into monoclonal plasma cells. This model indicates that a close cooperation between transformed cells and cytokineproducing cells may be a major mechanism in the progression of MM (2) and also has two apparent clinical implications . First, the culture of PBMC in the presence of IL-3 + IL-6 may be a simple assay to monitor the patient's response to the treatment and to assess a complete remission. Second, the burst of proliferative activity observed after 3 d of culture of PBMC in presence of IL-3 + IL-6 may be applied to the cytogenetic investigation of MM patients that is usually performed on BM samples and provides unsatisfactory results because of the very low fraction of cells in DNA synthesis (23). Summary PBMC from 11 patients with multiple myeloma (MM) were cultured in vitro in presence of IL-3 and IL-6. After 3 d, actively proliferating immunoblast-like B cells (20-62%) were apparent . After 6 d, a population of morphologically evident plasma cells was observed (30-50%) that expressed, in each individual case, the same light and heavy chain produced by bone marrow malignant plasma cells. We conclude that in MM the malignant plasma cell precursors are circulating and their growth and terminal differentiation are under the synergistic control of IL-3 and IL-6. 
